China Ossotide Market, 2010-2019 - New Market Research Report

According to statistics, the incidence of rheumatoid arthritis (RA) is 0.2%-0.36% and the number of cases is 5-10 million in China. Apart from RA, osteoarthritis, an expression of degraded joint function, is also common to see. With the ageing population in China, over 60% of elder people aged above 60 suffer from osteoarthritis, says a study. Patients with osteoarthritis typically show reduced mobility and life quality caused by joint pain, malformation and joint dysfunction.
Ossotide can not only regulate bone metabolism, stimulate osteoblast proliferation, accelerate new bone formation but also regulate calcium-phosphorus metabolism, increase calcium deposits so as to prevent osteoporosis. Ossotide injection and compound ossotide injection was first developed by Nanjing Xinbai Pharmaceutical Co., Ltd which was formerly Nanjing Biochemical Pharmaceutical Factory. In recent years, compound ossotide injection market has shown increasingly fierce competition as it is going from short supply to oversupply, from huge profits to meager profit. Besides, the rise in raw material price has stressed the profit margins.
After entering China market, ossotide is generally growing despite a decline in 2013 with annual sales value rising from less than CNY 60 million in 2005 to CNY 464 million in 2014 and CAGR during this period reaching over 26%. According to CRI's market survey, ossotide in the Chinese market mainly come from Harbin Medisan Pharmaceutical Co., Ltd, ZBD Pharmaceutical, Heilongjiang Jiangshi Pharmaceutical Co., Ltd, among which Harbin Medisan Pharmaceutical Co., Ltd has the largest market share of about 19% for sales value in 2014.
The market size of ossotide is expected to keep growing in the next few years in China.

Full Report Details at
- http://www.fastmr.com/prod/1015945_china_ossotide_20102019.aspx?afid=301

Readers can get at least the following information from this report:

* market size of ossotide in China
* competitive landscape of ossotide in Chinese market
* price of ossotide made by different enterprises in China
* market outlook of ossotide in China

The author suggests the following groups of people purchase this report:

* manufacturers of drugs for bones and muscles
* investors/ research institutions interested in Chinese medicine market
* any interest in the Chinese medicine market, please contact CRI for customized survey service

Companies Mentioned in this Report: Harbin Sanctity Pharmaceutical Co., Ltd, Harbin Medisan Pharmaceutical Co., Ltd, Heilongjiang Jiangshi Pharmaceutical Co., Ltd, Harbin Songhe Pharmaceutical Co., Ltd, Kaifeng Canon Pharmaceutical Co., Ltd

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)